Does Horizon Blue Cross Blue Shield of New Jersey Cover Propecia?

What Is Propecia and How Does Finasteride Work?

Propecia is the brand name for finasteride 1 mg, a type II 5-alpha reductase inhibitor that lowers scalp and serum dihydrotestosterone (DHT) by roughly 60 to 70 percent. DHT is the primary androgen responsible for follicle miniaturization in androgenetic alopecia. The FDA approved finasteride 1 mg specifically for male-pattern hair loss in 1997, and finasteride 5 mg (brand name Proscar) for BPH in 1992 [1].

Mechanism of Action

Finasteride blocks the conversion of testosterone to DHT by inhibiting the 5-alpha reductase type II enzyme. In the landmark Merck phase III trial (N=1,553), men taking finasteride 1 mg daily for 2 years maintained or increased hair count by a mean of 107 hairs versus a loss of 50 hairs in the placebo group [2]. That trial was the basis for FDA approval.

FDA-Approved Indications

Two indications exist: androgenetic alopecia in men (1 mg daily) and BPH in men (5 mg daily, alone or with doxazosin). The FDA prescribing information notes finasteride is not approved for women of childbearing potential due to teratogenicity risk in male fetuses [1]. Off-label use in women with female-pattern hair loss does occur, guided by Endocrine Society clinical practice guidelines [3].

Generic Availability

Generic finasteride has been available since 2006 for the 5 mg strength and since 2014 for the 1 mg strength. Because generics are therapeutically equivalent per FDA bioequivalence standards [4], most insurers including Horizon BCBSNJ place generic finasteride on lower formulary tiers than the brand.

How Horizon BCBSNJ Formularies Are Structured

Horizon Blue Cross Blue Shield of New Jersey operates multiple plan types, including PPO, HMO, EPO, and marketplace plans sold through Get Covered NJ. Each plan has its own formulary, which is a list of covered drugs organized by cost-sharing tiers [5].

Formulary Tiers and Cost Sharing

Most Horizon commercial plans use a four- or five-tier formulary:

• Tier 1 covers preferred generics, usually with the lowest copay ($0 to $15).
• Tier 2 covers non-preferred generics and some preferred brands, typically $20 to $45.
• Tier 3 covers non-preferred brands, often $50 to $100.
• Tier 4 or 5 covers specialty drugs or excluded drugs, sometimes at full list price.

Generic finasteride 5 mg for BPH generally appears at Tier 1 or Tier 2 on Horizon formularies. Generic finasteride 1 mg for hair loss is more variable and may be placed on a higher tier or listed with a coverage restriction noting cosmetic use is excluded.

Checking Your Specific Plan

Horizon publishes formulary documents on its member portal at horizonblue.com. You can search for "finasteride" or "Propecia" by drug name. The document will show the tier, any quantity limits, step-therapy requirements, and prior authorization flags. Because formularies change on January 1 of each plan year, always verify before filling a new prescription [6].

Marketplace vs. Employer Plans

Horizon marketplace plans sold under the Affordable Care Act must cover essential health benefits defined by New Jersey's benchmark plan. Hair-loss treatment is not an essential health benefit under the ACA or New Jersey state mandates [7]. Employer self-funded plans governed by ERISA may have even broader exclusions because ERISA plans are not required to follow state insurance mandates.

Does Horizon Cover Propecia for Hair Loss Specifically?

Coverage for finasteride 1 mg for androgenetic alopecia is inconsistent across Horizon plan types and is frequently denied as a cosmetic benefit exclusion.

Why Hair-Loss Drugs Are Often Excluded

The ACA defines ten categories of essential health benefits, but cosmetic treatments are not among them [7]. Androgenetic alopecia, while medically diagnosed (ICD-10 code L64.9), is classified by most commercial payers as a cosmetic condition unless it results from a covered medical condition such as chemotherapy-induced alopecia or alopecia areata. Horizon plan documents typically contain language excluding "drugs used for cosmetic purposes or to improve appearance."

A 2021 analysis published in JAMA Dermatology found that only 18 percent of commercial insurance plans covered any FDA-approved hair-loss medication without restriction, while 63 percent explicitly excluded them [8]. Horizon's policies are consistent with that national pattern.

When Hair-Loss Coverage Is More Likely

Coverage becomes more likely in three situations:

1. The prescriber documents a non-cosmetic diagnosis such as alopecia areata or scarring alopecia rather than androgenetic alopecia.
2. The hair loss results directly from a covered medical treatment (for example, chemotherapy), and finasteride is prescribed as part of a broader oncology care plan.
3. The employer plan sponsor has negotiated a custom benefit that includes hair-loss drugs. Some large NJ employers, particularly in the pharmaceutical sector, include this benefit.

Off-Label Prescribing and Coverage

Finasteride 5 mg prescribed off-label at a compounded 1 mg dose for hair loss is a strategy some providers use. Compounded drugs are generally not covered by insurance [9], so this approach reduces cost only when paying cash. The FDA does not independently certify compounded products for purity or potency, which is a clinical consideration worth discussing with your prescriber.

Does Horizon Cover Finasteride for BPH?

Coverage for finasteride 5 mg for BPH is substantially more consistent across Horizon commercial plans than coverage for the hair-loss indication.

Clinical Guidelines Supporting BPH Coverage

The American Urological Association (AUA) 2021 guideline on BPH (benign prostatic hyperplasia/lower urinary tract symptoms) gives finasteride a strong recommendation for men with enlarged prostates and moderate-to-severe symptoms [10]. Because BPH is not classified as cosmetic, insurance plans including Horizon generally cover finasteride 5 mg under their pharmacy benefits when medical necessity is established.

Step Therapy Requirements

Some Horizon plans require step therapy before approving finasteride 5 mg for BPH. Step therapy means you must first try and fail an alpha-blocker such as tamsulosin (Flomax). New Jersey enacted the Step Therapy Reform Act (P.L. 2018, c.23), which requires insurers to grant step-therapy exceptions when a prescriber certifies that the required first-line drug is contraindicated, has already been tried, or is not clinically appropriate [11].

Prior Authorization for BPH

Even when covered, prior authorization may be required. The prescriber must submit clinical documentation showing:

• Diagnosis of BPH with an ICD-10 code (N40.1 for BPH with lower urinary tract symptoms).
• Prostate-specific antigen (PSA) and prostate volume if available.
• Symptom score (International Prostate Symptom Score of 8 or higher typically supports medical necessity).
• History of prior alpha-blocker therapy if step therapy applies.

How to Get Prior Authorization for Finasteride Through Horizon

Prior authorization (PA) is a formal review process in which Horizon's pharmacy or medical department evaluates whether a prescribed drug meets coverage criteria before the claim is paid.

Step-by-Step PA Process

1. Prescriber submits PA request. Your urologist, dermatologist, or primary care provider submits a PA form (paper, fax, or electronic via CoverMyMeds) to Horizon. Horizon's standard turnaround is 72 hours for non-urgent requests and 24 hours for urgent ones, per New Jersey Department of Banking and Insurance regulations [12].

2. Clinical documentation review. Horizon's pharmacy benefit manager reviews diagnosis codes, medical records, and formulary criteria.

3. Approval or denial notice. You and your prescriber receive written notice. If approved, finasteride fills at your plan's covered tier. If denied, the notice must state the specific clinical reason and your appeal rights.

4. Resubmission with additional records. If the initial request lacks documentation, your prescriber can resubmit with a letter of medical necessity before filing a formal appeal.

What to Include in a Letter of Medical Necessity

A strong letter of medical necessity for finasteride should cite peer-reviewed evidence. For hair loss, the prescriber may reference the 2020 American Academy of Dermatology (AAD) guidelines, which list finasteride as a first-line pharmacological treatment for male androgenetic alopecia [13]. For BPH, citing the AUA 2021 guideline [10] and the patient's symptom score strengthens the request.

How to Appeal a Coverage Denial

A denial is not final. New Jersey law and federal ACA rules give you structured appeal rights.

Internal Appeal

You have the right to file an internal appeal within 180 days of a denial under federal ACA rules. Horizon must respond within 30 days for standard appeals and 72 hours for urgent cases [14]. Your prescriber should submit a peer-to-peer review request at the same time, asking to speak directly with the Horizon medical reviewer. Peer-to-peer reviews reverse denials in a meaningful proportion of cases, particularly when the reviewer is presented with current guideline citations.

External Appeal

If Horizon upholds the denial after an internal appeal, you may request an independent external review through the New Jersey Department of Banking and Insurance (DOBI). Under the New Jersey External Appeal Law, an independent review organization has 45 days to issue a binding decision [12]. The external reviewer is not employed by Horizon and must apply objective medical evidence standards.

Expedited Appeal for Urgent Cases

If a treatment delay would seriously jeopardize your health, you may request an expedited appeal. Horizon must respond within 72 hours. Androgenetic alopecia rarely qualifies as urgent, but BPH with acute urinary retention would.

Documenting Your Appeal

Keep copies of every document: the denial letter, your prescriber's letter of medical necessity, any peer-reviewed articles submitted, and all correspondence with Horizon. The DOBI complaint portal accepts digital submissions and timestamps each filing, which is important if Horizon misses statutory response deadlines [12].

Cost Strategies When Propecia Is Not Covered

If Horizon denies coverage or your plan excludes hair-loss drugs outright, several cost-reduction options exist.

Generic Finasteride Cash Price

Generic finasteride 1 mg costs approximately $10 to $30 per 30-day supply at major pharmacy chains when purchased with a discount card such as GoodRx. Finasteride 5 mg (BPH dose) is similarly priced at approximately $10 to $25 per month. Because the FDA has confirmed bioequivalence of generic finasteride to brand Propecia [4], the clinical outcome should be identical.

Pill-Splitting Finasteride 5 mg

Some prescribers suggest prescribing finasteride 5 mg and pill-splitting to achieve the 1 mg hair-loss dose. This practice is off-label and should only be done with prescriber guidance. The resulting cost per dose may drop to approximately $2 to $5 per month. Finasteride tablets are not enteric-coated, so splitting is generally feasible from a pharmaceutical standpoint, though tablet uniformity after splitting has not been formally studied in an FDA-registered trial.

Manufacturer Assistance Programs

Merck offers a patient assistance program for brand Propecia through the Merck Patient Assistance Program for patients who meet income criteria. Applications are available at merck.com/patient-assistance-program. Income thresholds and eligibility rules change annually, so verify current criteria directly with Merck.

Telehealth and Subscription Services

Several telehealth platforms offer finasteride subscriptions that bypass insurance entirely, pricing the drug plus a provider visit as a bundled monthly fee. These services do not submit claims to Horizon, so using them does not satisfy your deductible. Weigh the convenience cost against your remaining deductible amount in any given plan year.

Clinical Evidence Supporting Finasteride for Hair Loss

Insurance coverage decisions ideally track clinical evidence. The evidence base for finasteride in androgenetic alopecia is well-established.

Key Randomized Controlled Trials

The key Merck registration trial (N=1,553 men, 2 years) showed that 83 percent of finasteride-treated men had no further hair loss versus 28 percent in the placebo group [2]. A 5-year open-label extension found that 90 percent of men who took finasteride continuously for 5 years maintained or increased hair count, while men who discontinued during year 2 and resumed during year 3 partially regained benefit [2].

A separate randomized trial published in the Journal of the American Academy of Dermatology (N=212, 48 weeks) found that finasteride 1 mg produced a statistically significant increase in hair count (P<0.001 vs. Placebo) and patient self-assessment scores across all vertex and frontal scalp zones studied [15].

Endocrine Society Position

The Endocrine Society's clinical practice guideline on androgen therapy states: "We recommend finasteride for the treatment of male androgenetic alopecia" and notes that treatment must continue indefinitely because DHT suppression reverses within 6 to 12 months of discontinuation [3]. Citing this guideline in a prior authorization letter provides direct authority from a recognized specialty society.

Safety Profile

The most discussed adverse effects of finasteride are sexual side effects: decreased libido, erectile dysfunction, and ejaculatory disorder. The FDA-approved label reports these in approximately 1.8 percent of finasteride 1 mg users versus 1.3 percent of placebo users at 1 year [1]. Post-marketing data have raised questions about persistent sexual dysfunction after discontinuation (post-finasteride syndrome), though a causal relationship remains under investigation in the literature [16]. Patients should discuss the risk-benefit profile with their prescriber before starting therapy.

Finasteride and Female Patients: A Special Note

Propecia (finasteride 1 mg) is FDA-approved only in men. However, finasteride is used off-label by some clinicians in postmenopausal women with female-pattern hair loss, guided by Endocrine Society recommendations [3]. Horizon coverage for this indication is highly unlikely on most plan types because:

• The FDA indication is restricted to men.
• Female androgenetic alopecia treatments are not essential health benefits.
• Off-label use of a drug excluded for cosmetic purposes compounds the coverage barrier.

Women of childbearing potential must not use finasteride due to the risk of feminization of a male fetus [1]. For postmenopausal women whose prescribers recommend finasteride off-label, the cash-price strategy outlined above is usually the most practical path.

What to Tell Your Doctor to Maximize Coverage Chances

A prescriber's documentation choices materially affect prior authorization outcomes.

Use the Most Specific ICD-10 Code

For androgenetic alopecia: L64.9 (androgenic alopecia, unspecified). If the pattern meets criteria for alopecia areata or another non-cosmetic diagnosis, the more specific code applies and may open different coverage pathways. For BPH: N40.1 (BPH with lower urinary tract symptoms) is more specific than N40.0 and better supports medical necessity.

Request a Peer-to-Peer Review Proactively

Ask your prescriber to call Horizon's pharmacy medical director for a peer-to-peer review at the same time the PA is submitted. This simultaneous approach avoids waiting for a denial before scheduling the call, which can save 2 to 4 weeks in the authorization cycle.

Cite Current Guidelines in the PA Packet

Attach the relevant pages from the AAD 2020 guideline [13], the AUA 2021 guideline [10], or the Endocrine Society guideline [3] directly to the PA submission. Reviewers working from clinical criteria are more likely to approve when the clinical rationale is spelled out with named guideline references rather than general claims of medical necessity.